PMID- 27537990
OWN - NLM
STAT- MEDLINE
DCOM- 20170425
LR  - 20170425
IS  - 1545-9616 (Print)
IS  - 1545-9616 (Linking)
VI  - 15
IP  - 8
DP  - 2016 Aug 1
TI  - Effect of Psoriatic Arthritis on Treatment Response in Patients With Moderate to 
      Severe Psoriasis.
PG  - 917-22
AB  - BACKGROUND: Among patients with moderate-to-severe psoriasis, efficacy, and 
      tolerability of available treatments based on psoriatic arthritis (PsA) history 
      are not well-described.<BR /> OBJECTIVE: We evaluate disease characteristics and 
      treatment response variation in the moderate-to-severe psoriasis population based 
      on PsA history.<BR /> METHODS: Simple-measure for assessing psoriasis activity 
      (S-MAPA) was used to retrospectively analyze treatment responses.<BR /> RESULTS: 
      191 moderate-to-severe psoriatic patients, 58 with and 133 without 
      rheumatologist-diagnosed PsA were analyzed. Regardless of PsA history, S-MAPA 
      improvement was similar with biologic monotherapy (46.2 versus 44.1; 
      <em>P</em>=0.74), traditional systemic monotherapy (62.29 versus 38.12; 
      <em>P</em>=0.22), and combination treatments (64.62 versus 52.71; 
      <em>P</em>=0.40) after 12 weeks. PsA patients on biologic monotherapy experienced 
      a higher infection rate than patients without PsA (0.57% versus 0.19%; 
      <em>P</em>=0.01). PsA patients experienced more adverse events (AEs) associated 
      with traditional systemic monotherapy than biologic monotherapy (3.25 versus 
      1.04; <em>P</em>=.001).<BR /> LIMITATIONS: The relatively small PsA cohort was 
      the primary limitation.<BR /> CONCLUSIONS: Patients with moderate-to-severe 
      psoriasis responded similarly to all treatments independent of PsA history. PsA 
      patients received more overall treatments and more biologic monotherapy 
      prescriptions. PsA patients had a greater infection risk on biologic monotherapy 
      compared to those without PsA, and greater adverse events risk on traditional 
      systemic monotherapy compared to biologic monotherapy.<BR /><BR /> <EM>J Drugs 
      Dermatol</EM>. 2016;15(8):917-922.
FAU - Greb, Jacqueline E
AU  - Greb JE
FAU - Garber, Caren
AU  - Garber C
FAU - Gottlieb, Alice B
AU  - Gottlieb AB
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Drugs Dermatol
JT  - Journal of drugs in dermatology : JDD
JID - 101160020
RN  - 0 (Biological Products)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Arthritis, Psoriatic/*diagnosis/*drug therapy
MH  - Biological Products/*administration & dosage
MH  - Cross-Sectional Studies
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - *Severity of Illness Index
MH  - Treatment Outcome
EDAT- 2016/08/19 06:00
MHDA- 2017/04/26 06:00
CRDT- 2016/08/19 06:00
PHST- 2016/08/19 06:00 [entrez]
PHST- 2016/08/19 06:00 [pubmed]
PHST- 2017/04/26 06:00 [medline]
AID - S1545961616P0917X [pii]
PST - ppublish
SO  - J Drugs Dermatol. 2016 Aug 1;15(8):917-22.